PATH Study

PATH Study: Continued Access to HIV Treatment for Children and Adolescents

Rationale 

The PATH Study is a Phase 3b continued-access study providing ongoing access to HIV treatment for eligible participants transitioning from ViiV Healthcare-sponsored or collaborative parent studies. The study supports participants who continue to benefit from their treatment but do not have access to the same treatment through locally available options after completing their parent study.

Aim of the Study

The study aims to:

• Provide continued access to study treatment for eligible participants transitioning from parent studies.
• Monitor the continued use and safety of the study intervention.
• Document treatment discontinuation and serious or other important adverse events during continued treatment.

Study Population

Participants transitioning from eligible ViiV Healthcare-sponsored or collaborative parent studies who continue to benefit from their study treatment.

Investigators

• Dr Faeezah Patel – Principal Investigator
• Prof Lee Fairlie – Sub-Investigator
• Dr Elizea Horne – Sub-Investigator
• Dr Mrinmayee Dhar – Sub-Investigator
• Dr Jeanne Coetzee – Sub-Investigator

Sponsor: Fondazione Penta – for the treatment and care of children with HIV and related diseases (ONLUS)
Funder: ViiV Healthcare
Study Contacts: Kabelo Mashaba / Dr Faeezah Patel

Latest Updated: July 2026

For more details about the PATH Study please email rhicomms@wrhi.ac.za